India  

Covid-19: Interim clinical efficacy of Covaxin is 81%, says Bharat Biotech

IndiaTimes Wednesday, 3 March 2021
0
shares
ShareTweetSavePostSend
 
Video Credit: ANI - Published
News video: 'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech 01:42

Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial. "Today is an important day for us, country and Indian science. COVAXIN has demonstrated an interim vaccine efficacy of around 80.6% in its Phase 3 clinical trial. The...

💡 newsR Knowledge: Other News Mentions

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

Time to put vaccines at medical stores to beat Covid wave? Top doctors answer [Video]

Time to put vaccines at medical stores to beat Covid wave? Top doctors answer

With the second wave of Covid-19 infections putting pressure on India's healthcare infrastructure, top doctors comment on how the government can update its vaccination strategy. Doctors Jalil Parkar and Amit Thadhani spoke on the need to widen the vaccination net, and also include the private sector to a greater degree. Watch the full video for more.

Credit: HT Digital Content    Duration: 03:44Published
'4 people on 1 bed': Patients' relatives on ordeal at Delhi hospitals | Covid [Video]

'4 people on 1 bed': Patients' relatives on ordeal at Delhi hospitals | Covid

Relatives of patients admitted to Delhi hospitals for Covid-19 treatment recounted their ordeal amid an unprecedented surge in cases. The patients' relatives said they found admission after being rejected by multiple hospitals. One of them claimed that 4 people were being housed on a single bed, while another stated that her relative had been asked to lie down on the floor, and was being denied food and water. Delhi saw 25,500+ new Covid cases in 24 hours, the highest single-day surge so far. Watch the full video for more.

Credit: HT Digital Content    Duration: 02:15Published
Germany mourns its 80,000 Covid dead at memorial [Video]

Germany mourns its 80,000 Covid dead at memorial

Germany, represented by Chancellor Angela Merkel and President Frank-Walter Steinmeier, holds a national memorial service in a Berlin concert hall for its nearly 80,000 victims of the coronavirus pandemic.

Credit: euronews (in English)    Duration: 01:00Published

COVID-19 second wave: Indian Railways to run oxygen express via green corridors soon

Availability of oxygen is a key element in the treatment of certain medical conditions in the Covid infection, said a release by the ministry.
DNA

BBV152 BBV152 Vaccine against COVID-19

Use entire national capacity to step up Covid vaccine production, PM tells officials

The PM’s directive came at a review meeting on the Covid situation on Saturday a day after he had overseen an assessment of oxygen supplies and production and..
IndiaTimes

Covaxin production to be increased to 100 million doses per month by September 2021: Centre

Union health minister Harsh Vardhan said financial support is being provided to four manufacturers to expand Covaxin vaccine production.
DNA

India to increase Covaxin production to 100 million doses per month by September

The Union government on Friday said it will amp up the production of the indigenously developed Covaxin vaccine to 100 million doses per month by September. As..
IndiaTimes
Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin [Video]

Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin

The Central Government has given permission to Haffkine Institute to produce Bharat Biotech's Covaxin. CM Uddhav Thackeray thanked PM Modi through a tweet by CM office, Maharashtra on April 15, "The Dept of Science and Technology, Government of India, has granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis. CM Uddhav Balasaheb Thackeray has thanked the Hon'ble PM Shri@narendramodi for approving this request."

Credit: ANI    Duration: 01:14Published

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Even as Covid vaccine demand rises, firms may take some weeks to up production

Indications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and..
IndiaTimes

You Might Like